The analysis, presented at AHA Scientific Sessions 2021, included approximately 2,000 symptomatic COVID-19 patients who were not necessarily sick enough to be hospitalized.
Once the tool's performance is properly validated, it could help clinicians deliver better patient care and result in significant cost savings for health systems.